References
-
Chen XT, Pitis P, Liu G, Yuan C, Gotchev D, Cowan CL, et al. Structure-activity relationships and discovery of a G protein biased
${\mu}$ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6- oxaspiro-[4.5]de can-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. J Med Chem 2013; 56: 8019-31. https://doi.org/10.1021/jm4010829 -
Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, et al. Regulation of
${\mu}$ -opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 2013; 65: 223-54. https://doi.org/10.1124/pr.112.005942 - Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol 2003; 63: 1256-72. https://doi.org/10.1124/mol.63.6.1256
- Kochman K. Superfamily of G-protein coupled receptors (GPCRs)--extraordinary and outstanding success of evolution. Postepy Hig Med Dosw (Online) 2014; 68: 1225-37. https://doi.org/10.5604/17322693.1127326
- Schioth HB, Fredriksson R. The GRAFS classification system of G-protein coupled receptors in comparative perspective. Gen Comp Endocrinol 2005; 142: 94-101. https://doi.org/10.1016/j.ygcen.2004.12.018
- Smith HS. Peripherally-acting opioids. Pain Physician 2008; 11: S121-32.
- Sehgal N, Smith HS, Manchikanti L. Peripherally acting opioids and clinical implications for pain control. Pain Physician 2011; 14: 249-58.
- Burness CB, Keating GM. Oxycodone/naloxone prolongedrelease: a review of its use in the management of chronic pain while counteracting opioid-induced constipation. Drugs 2014; 74: 353-75. https://doi.org/10.1007/s40265-014-0177-9
- Morlion B, Clemens KE, Dunlop W. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone. Clin Drug Investig 2015; 35: 1-11.
- Violin JD, Crombie AL, Soergel DG, Lark MW. Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci 2014; 35: 308-16. https://doi.org/10.1016/j.tips.2014.04.007
- Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science 1999; 286: 2495-8.
- Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG. Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature 2000; 408: 720-3. https://doi.org/10.1038/35047086
- Raehal KM, Walker JK, Bohn LM. Morphine side effects in beta-arrestin 2 knockout mice. J Pharmacol Exp Ther 2005; 314: 1195-201.
- Soergel DG, Subach RA, Sadler B, Connell J, Marion AS, Cowan CL, et al. First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol 2014; 54: 351-7. https://doi.org/10.1002/jcph.207
-
Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, et al. Biased agonism of the
${\mu}$ -opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, doubleblind, placebo-controlled, crossover study in healthy volunteers. Pain 2014; 155: 1829-35. -
Fossler M, Sadler B, Farrell C, Burt D, Pitsiu M, Skobieranda F, et al. (342) Oliceridine (TRV130), a novel
${\mu}$ receptor G protein pathway selective modulator (${\mu}$ -GPS), demonstrates a predictable relationship between plasma concentrations and pain relief. I: development of a pharmacokinetic/pharmacodynamic (PK/PD) model. J Pain 2016; 17: S61. -
Fossler M, Sadler B, Farrell C, Burt D, Pitsiu M, Skobieranda F, et al. (343) Oliceridine (TRV130), a novel
${\mu}$ receptor G protein pathway selective modulator (${\mu}$ -GPS), demonstrates a predictable relationship between plasma concentrations and pain relief. II: simulation of potential dosing regimens using a pharmacokinetic/pharmacodynamic (PK/PD) model. J Pain 2016; 17: S61. -
Viscusi E, Minkowitz H, Webster L, Soergel D, Burt D, Subach R, et al. (433) Rapid reduction in pain intensity with oliceridine (TRV130), a novel
${\mu}$ receptor G protein pathway selective modulator (${\mu}$ -GPS), vs. morphine: an analysis of two phase 2 randomized clinical trials. J Pain 2016; 17:S82-3. -
Singla N, Minkowitz H, Soergel D, Burt D, Skobieranda F. (432) Respiratory safety signal with oliceridine (TRV130), a novel
${\mu}$ receptor G protein pathway selective modulator (${\mu}$ -GPS), vs morphine: a safety analysis of a phase 2b randomized clinical trial. J Pain 2016; 17: S82. -
Minkowitz H, Singla N, Soergel D, Burt D, Skobieranda F. (435) Nausea and vomiting with oliceridine (TRV130), a novel
${\mu}$ receptor G protein pathway selective modulator (${\mu}$ -GPS), vs morphine: an analysis of tolerability from a phase 2b randomized clinical trial. J Pain 2016; 17: S83. -
Viscusi ER, Webster L, Kuss M, Daniels S, Bolognese JA, Zuckerman S, et al. A randomized, phase 2 study investigating TRV130, a biased ligand of the
${\mu}$ -opioid receptor, for the intravenous treatment of acute pain. Pain 2016; 157: 264-72. - Madariaga-Mazon A, Marmolejo-Valencia AF, Li Y, Toll L, Houghten RA, Martinez-Mayorga K. Mu-Opioid receptor biased ligands: a safer and painless discovery of analgesics? Drug Discov Today 2017; 22: 1719-29. https://doi.org/10.1016/j.drudis.2017.07.002
- Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002; 3: 639-50. https://doi.org/10.1038/nrm908
- Jacoby E, Bouhelal R, Gerspacher M, Seuwen K. The 7 TM G-protein-coupled receptor target family. ChemMedChem 2006; 1: 760-82. https://doi.org/10.1002/cmdc.200600134
- McCudden CR, Hains MD, Kimple RJ, Siderovski DP, Willard FS. G-protein signaling: back to the future. Cell Mol Life Sci 2005; 62: 551-77. https://doi.org/10.1007/s00018-004-4462-3
- Patel TB. Single transmembrane spanning heterotrimeric G protein-coupled receptors and their signaling cascades. Pharmacol Rev 2004; 56: 371-85. https://doi.org/10.1124/pr.56.3.4
-
Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of
${\beta}$ -arrestin- and G protein-biased agonists. Trends Mol Med 2011; 17: 126-39. https://doi.org/10.1016/j.molmed.2010.11.004 - Kliewer A, Reinscheid RK, Schulz S. Emerging paradigms of G protein-coupled receptor dephosphorylation. Trends Pharmacol Sci 2017; 38: 621-36. https://doi.org/10.1016/j.tips.2017.04.002
- Dang VC, Christie MJ. Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons. Br J Pharmacol 2012; 165: 1704-16. https://doi.org/10.1111/j.1476-5381.2011.01482.x
- Allouche S, Noble F, Marie N. Opioid receptor desensitization: mechanisms and its link to tolerance. Front Pharmacol 2014; 5: 280.
- Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ 2002; 167: 1131-7.
- Del Vecchio G, Spahn V, Stein C. Novel opioid analgesics and side effects. ACS Chem Neurosci 2017; 8: 1638-40. https://doi.org/10.1021/acschemneuro.7b00195
- Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G, et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature 2016; 537: 185-90.
- Siuda ER, Carr R 3rd, Rominger DH, Violin JD. Biased mu-opioid receptor ligands: a promising new generation of pain therapeutics. Curr Opin Pharmacol 2017; 32: 77-84.
Cited by
- Molecular Dynamics Simulations to Investigate How PZM21 Affects the Conformational State of the μ-Opioid Receptor Upon Activation vol.21, pp.13, 2020, https://doi.org/10.3390/ijms21134699
- Advances in Oncoanaesthesia and Cancer Pain vol.29, pp.None, 2018, https://doi.org/10.1016/j.ctarc.2021.100491
- Endogenous opiates and behavior: 2019 vol.141, pp.None, 2018, https://doi.org/10.1016/j.peptides.2021.170547
- Pharmacological Advances in Opioid Therapy: A Review of the Role of Oliceridine in Pain Management vol.10, pp.2, 2018, https://doi.org/10.1007/s40122-021-00313-5
- G protein-coupled receptors: structure- and function-based drug discovery vol.6, pp.1, 2018, https://doi.org/10.1038/s41392-020-00435-w